Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced an additional private placement financing with entities associated with TCGX, an institutional investor, for a private placement of 1,000,000 shares of its common stock. The common stock issued to the private placement investors at closing will be priced at $68.48 per share, resulting in approximately $68.5 million in gross proceeds.
This private placement, together with Mirum’s $200 million private placement announced earlier in the month, is intended to fund clinical development and commercial activities following the proposed acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. Both private placements are expected to close concurrently with the proposed acquisition of Bluejay, anticipated in the first quarter of 2026, subject to regulatory approval and other customary closing conditions.
Mirum Pharmaceuticals' commercial portfolio includes Livmarli® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), Cholbam® (cholic acid) for bile-acid synthesis disorders, and Ctexli® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Their clinical-stage pipeline includes Volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), and MRM-3379, a PDE4D inhibitor being evaluated for fragile X syndrome (FXS).
Mirum Pharmaceuticals' success is driven by a team dedicated to advancing high-impact medicines through strategic development, disciplined execution, and purposeful collaboration across the rare disease ecosystem. The market has reacted to these announcements by moving the company's shares 10.5% to a price of $77.66. Check out the company's full 8-K submission here.
